Investorideas.com newswire, stock news and business news for investors

Tuesday, July 21, 2015

Aethlon Medical (NasdaqCM: AEMD) to Ring the Nasdaq Stock Market Closing Bell on July 24th

Aethlon Medical (NasdaqCM: AEMD) to Ring the Nasdaq Stock Market Closing Bell on July 24th

SAN DIEGO - July 21, 2015 (Investorideas.com newswire) Aethlon Medical, Inc. (NasdaqCM:AEMD), the pioneer in creating affinity biofiltration devices to treat life-threatening diseases, today announced that the Company will ring the Nasdaq Stock Market closing bell on Friday, July 24, 2015 in honor of its recent listing on the Nasdaq Capital Market. Attending the event on behalf of Aethlon Medical will be Jim Joyce, Chairman and Chief Executive Officer and Jim Frakes, Chief Financial Officer.


"Ringing the closing bell marks an exciting time for our Company both in regards to our recent Nasdaq listing and the opportunities for our Aethlon Hemopurifier® to play a critical role in the elimination of infectious viruses and cancer promoting exosomes from the circulatory system," stated Jim Joyce, Chairman and CEO of Aethlon Medical.

The event will take place at the Nasdaq MarketSite in Times Square on Friday, July 24th from 3:45 p.m. to 4:00 p.m. ET.


About Aethlon Medical, Inc.
Aethlon Medical creates affinity biofiltration devices to treat life-threatening diseases. Our lead therapeutic candidate is the Aethlon Hemopurifier®, a first-in-class device that targets the rapid elimination of infectious viruses and cancer-promoting exosomes from the circulatory system of treated individuals. U.S. clinical progression of Hemopurifier therapy is being advanced under an FDA approved clinical study. We also provide government contracting services to the Defense Advanced Research Projects Agency related to the development of a biofiltration device to treat sepsis. Additional information can be found online at www.AethlonMedical.com or you can connect with us on on Twitter, LinkedIn, Facebook and Google+.

Certain statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, that the ESI will not be able to commercialize its future products, that the FDA will not approve the initiation of the Company's clinical programs or provide market clearance of the company's products, future human studies whether revenue or non-revenue generating of the Aethlon ADAPT™ system or the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer or hepatitis C therapies or as a standalone cancer or hepatitis C therapy or as a broad spectrum defense against viral pathogens, including Ebola, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, the ability of the Company to meet the milestones contemplated in the DARPA contract, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Contacts:
James A. Joyce 
Chairman and CEO
 
858.459.7800 x301
 
jj@aethlonmedical.com

Jim Frakes 
Chief Financial Officer
 
858.459.7800 x300
 
jfrakes@aethlonmedical.com

Brad Edwards/Sharon Oh 
Brainerd Communicators, Inc
 
212-986-6667
 
oh@braincomm.com

David Zazoff 
MDM Worldwide Solutions
 
646-403-3554

Visit this company: www.aethlonmedical.com

More info on AEMD at Investorideas.com Visit: http://www.investorideas.com/CO/AEMD/

Sign up for the free investor news and stock alerts:

Disclaimer/Disclosure: The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp Disclosure: AEMD subscribes to the Investorideas newswire content publishing annual program (9700 per Year, paid quarterly) for news publishing.
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.





Monday, July 13, 2015

Aethlon Medical (NasdaqCM: AEMD) Begins Trading on the Nasdaq Capital Market

Aethlon Medical (NasdaqCM: AEMD) Begins Trading on the Nasdaq Capital Market

SAN DIEGO - July 13, 2015 (Investorideas.com newswire) Aethlon Medical, Inc. (NasdaqCM:AEMD), the pioneer in creating affinity biofiltration devices to treat life-threatening diseases, today announced that the Company's common stock commenced trading on the Nasdaq Capital Market under the symbol "AEMD" at the opening of trading today.

The Company's application to have its common stock listed on the Nasdaq Capital Market was approved on July 8, 2015.




About Aethlon Medical, Inc.
Aethlon Medical creates affinity biofiltration devices to treat life-threatening diseases. Our lead therapeutic candidate is the Aethlon Hemopurifier®, a first-in-class device that targets the rapid elimination of infectious viruses and cancer-promoting exosomes from the circulatory system of treated individuals. U.S. clinical progression of Hemopurifier therapy is being advanced under an FDA approved clinical study. We also provide government contracting services to the Defense Advanced Research Projects Agency related to the development of a biofiltration device to treat sepsis. Additional information can be found online at www.AethlonMedical.com or you can connect with us on on Twitter, LinkedIn, Facebook and Google+.

Certain statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, that the ESI will not be able to commercialize its future products, that the FDA will not approve the initiation of the Company's clinical programs or provide market clearance of the company's products, future human studies whether revenue or non-revenue generating of the Aethlon ADAPT™ system or the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer or hepatitis C therapies or as a standalone cancer or hepatitis C therapy or as a broad spectrum defense against viral pathogens, including Ebola, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, the ability of the Company to meet the milestones contemplated in the DARPA contract, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Contacts:
James A. Joyce 
Chairman and CEO
 
858.459.7800 x301
 
jj@aethlonmedical.com

Jim Frakes 
Chief Financial Officer
 
858.459.7800 x300
 
jfrakes@aethlonmedical.com

Mike Smargiassi/Brad Edwards 
Brainerd Communicators, Inc
 
212-986-6667
 
smarg@braincomm.com

David Zazoff 
MDM Worldwide Solutions
 
646-403-3554

Visit this company: www.aethlonmedical.com

More info on AEMD at Investorideas.com Visit: http://www.investorideas.com/CO/AEMD/

Sign up for the free investor news and stock alerts:

Disclaimer/Disclosure: The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp Disclosure: AEMD subscribes to the Investorideas newswire content publishing annual program (9700 per Year, paid quarterly) for news publishing.
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.




Wednesday, July 8, 2015

Aethlon Medical (OTCQB: AEMD) Announces Nasdaq Capital Market Listing Approval

Medical Technology Breaking News: Aethlon Medical (OTCQB: AEMD) Announces Nasdaq Capital Market Listing Approval

SAN DIEGO - July 8, 2015 (Investorideas.com newswire) Aethlon Medical, Inc. (OTCQB:AEMD), the pioneer in creating affinity biofiltration devices to treat life-threatening diseases, today announced that the Company's application to list its common stock on the Nasdaq Capital Market has been approved by The NASDAQ Stock Market LLC. Aethlon's common stock is expected to begin trading on the Nasdaq Capital Market at the opening of market hours on Monday, July 13, 2015 under its existing trading symbol, AEMD.

"Trading on Nasdaq is a pivotal corporate milestone that will help raise the visibility of our therapeutic endeavors and increase the appeal of our shares to mutual funds, pension funds, and other institutional investors that may have previously been restricted from trading our shares," stated Jim Joyce, Chairman and CEO of Aethlon Medical.




About Aethlon Medical, Inc.
Aethlon Medical creates affinity biofiltration devices to treat life-threatening diseases. Our lead therapeutic candidate is the Aethlon Hemopurifier®, a first-in-class device that targets the rapid elimination of infectious viruses and cancer-promoting exosomes from the circulatory system of treated individuals. U.S. clinical progression of Hemopurifier therapy is being advanced under an FDA approved clinical study. We also provide government contracting services to the Defense Advanced Research Projects Agency related to the development of a biofiltration device to treat sepsis. Additional information can be found online at www.AethlonMedical.com or you can connect with us on on Twitter, LinkedIn, Facebook and Google+.

Certain statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, that the ESI will not be able to commercialize its future products, that the FDA will not approve the initiation of the Company's clinical programs or provide market clearance of the company's products, future human studies whether revenue or non-revenue generating of the Aethlon ADAPT™ system or the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer or hepatitis C therapies or as a standalone cancer or hepatitis C therapy or as a broad spectrum defense against viral pathogens, including Ebola, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, the ability of the Company to meet the milestones contemplated in the DARPA contract, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Contacts:
James A. Joyce 
Chairman and CEO
 
858.459.7800 x301
 
jj@aethlonmedical.com

Jim Frakes 
Chief Financial Officer
 
858.459.7800 x300
 
jfrakes@aethlonmedical.com

David Zazoff 
MDM Worldwide Solutions
 
646-403-3554

Visit this company: www.aethlonmedical.com

More info on AEMD at Investorideas.com Visit: http://www.investorideas.com/CO/AEMD/

Sign up for the free investor news and stock alerts:

Disclaimer/Disclosure: The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp Disclosure: AEMD subscribes to the Investorideas newswire content publishing annual program (9700 per Year, paid quarterly) for news publishing.
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.



Thursday, June 25, 2015

Media Alert for Vycor Medical, Inc. (OTCQB: VYCO);” Vycor Medical Offers Upside Through Vision Therapy” - Portfolio Guru

Media Alert for Vycor Medical, Inc. (OTCQB: VYCO);” Vycor Medical Offers Upside Through Vision Therapy” - Portfolio Guru

Point Roberts WA, NEW YORK, NY -- June 25, 2015 - Investorideas.com, a global news source covering leading sectors including biotech and medical technology issues a media alert for Vycor Medical, Inc (OTCQB:VYCO) and its NovaVision Vision Restoration Therapy. The company was recently featured in articles by Jim Collins, Portfolio Guru, LLC, published at TheStreet.com.

Articles:
An Eye for EYES, and Here's Why
TheStreet.com-Jun 19, 2015
Jim Collins

Today I'll return to one of my favorite ideas, Second Sight Medical ... I'll focus on another company in the vision field, Vycor Medical (VYCO). http://realmoney.thestreet.com/articles/06/19/2015/eye-eyes-and-heres-why

Follow up Article: Vycor Medical Offers Upside Through Vision Therapy
Jim Collins
Portfolio Guru, LLC
www.theportfolioguru.com

I wrote in Friday's column about Second Sight, whose Argus II retinal implant restores sight in patients with retinitis pigmentosa and will soon enter clinical trials for age-related macular degeneration. Both conditions are obviously degenerative, but what happens when sight is impaired due to a sudden condition? Two common causes of this would be stroke and traumatic brian injury (TBI).

That's where Vycor Medical (VYCO) comes in. The company's NovaVision suite of therapies offer ability to improve quality of vision--and thus quality of life--in patients who have suffered stroke or TBI.

Link to article:


About Vycor Medical, Inc.
With corporate headquarters in Boca Raton, FL, Vycor Medical, Inc. (“Vycor”) is a publicly traded company (OTCQB—VYCO) dedicated to providing the medical community with innovative and superior surgical and therapeutic solutions and has a growing portfolio of FDA cleared medical solutions that are changing and improving lives every day. The Company operates two business units: Vycor Medical and NovaVision, both of which adopt a minimally or non-invasive approach. Both technologies have exceptional sales growth potential, address large potential markets, have the requisite regulatory approvals and are commercialized and generating revenue.

Vycor Medical’s ViewSite™ Surgical Access Systems (VBAS) is a suite of clear cylindrical minimally invasive disposable devices that hold the potential for speedier, safer and more economical brain surgeries and a quicker patient discharge.  VBAS is designed to optimize neurosurgical site access, reduce patient risk, accelerate recovery and add tangible value to the professional medical community. The company is ISO 13485:2003 compliant, has U.S. FDA 510(k) clearance for brain and spine surgeries and full regulatory approvals for brain in Australia, Brazil, Canada, China, Europe (EU – Class III), Korea and Japan and is seeking or has partial regulatory approvals in India, Russia, Taiwan and Vietnam. For an overview of Vycor Medical’s VBAS see VBAS Video.

NovaVision develops and provides science-driven neurostimulation therapy and other medical technologies that help improve and partially restore sight in patients with neurological vision impairments.  The company’s proprietary Visual Restoration Therapy® (VRT) platform is clinically supported to improve lost vision resulting from Stroke, Traumatic Brain Injury (TBI), or other acquired brain injuries. VRT is the only FDA 510K cleared medical device in the U.S. aimed at the restoration of vision for neurologically induced vision loss and can be prescribed by any physician.  VRT also has CE Marking for the EU. NovaVision also provides Neuro Eye Therapy (NeET) in the EU, aimed at increasing visual sensitivity deep within the field defect.

The Company has also developed NeuroEyeCoach™, a therapy which is highly complementary to VRT™. The two therapies address different visual disabilities each of which results from neurologically-induced vision loss – a loss of visual field as well as difficulty with eye movement, affecting the ability to integrate visual information. VRT provides partial restoration of the patient’s lost visual field; NeuroEyeCoach™ is designed to increase the efficiency of eye movement and re-train the patients’ ability to integrate visual information between the left and right hand side. 

See the video on YouTube.com - NovaVision Vision Restoration Therapy


For the latest information on the company, including media and other coverage, and to learn more, please go online at www.vycormedical.com, www.vycorvbas.com or www.novavision.com.

InvestorIdeas.com newswire is a global investor news source covering leading sectors including medical technology and biotech.

Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas

Sign up for free news alerts at Investorideas.com

Become an Investorideas.com Member and access our online stock directories listing thousands of publicly traded stocks in leading sectors 

Disclaimer/ Disclosure: The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp (VYCO): June 2, 2015 – The company has retained Investor Ideas for PR, media and news distribution: Five thousand per month, one month with option to renew.
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894 . Global investors must adhere to regulations of each country.

Contact Investorideas.com
800 665 0411


Vycor (OTCQB:VYCO) Announces Commercial Release of Its NovaVision Web Deliverable Therapy Suite

"We are now finally in a position to deliver our therapies to the large numbers of people who suffer vision loss as a result of neurological brain damage as a cost effective and complete therapy solution" - CEO of Vycor

BOCA RATON, Florida - June 25, 2015 (Investorideas.com Newswire) - Vycor Medical, Inc. ("Vycor") (VYCO), a provider of innovative and superior surgical and therapeutic solutions, announced the commercial release of its Internet-delivered therapy suite in the U.S. This therapy suite, consisting of its lead Vision Restoration Therapy (VRT) and its NeuroEyeCoach eye-movement compensation therapy, is delivered directly to patients over the Internet onto their own computers replacing the Company's current "prototype hardware centric" model.

NovaVision has been working to take its VRT therapy prototype and develop it into an affordable, scalable therapy offering that offers broader patient benefits. VRT will going forward be provided alongside NovaVision's NeuroEyeCoach compensatory therapy in one Internet delivered therapy suite. Two things happen when someone suffers from vision related disorders following a stroke or brain injury: there is a loss of visual field as well as difficulty with eye movement, affecting the ability to integrate visual information. VRT addresses the restoration of lost vision while NeuroEyeCoach addresses patients' difficulty with their eye movements and their ability to integrate visual information, allowing them to make the most of their remaining vision, The two therapies provided in a suite are therefore highly complementary and ensure broad benefits to NovaVision's patients.

NovaVision is now positioned, for the first time, with the suite of therapies and product offerings to deliver on its strategic vision: to provide a clinically supported, affordable and scalable visual therapy solution offering broad benefits to those suffering visual impairment following neurological damage; and to offer solutions for both patients and physicians alike.

For Patients:
·        VRT and NeuroEyeCoach Therapy Suite. NovaVision will commercially launch this week these two complementary therapies, internet-delivered in a package for $900.
·        NeuroEyeCoach. For patients with visual impairments who are not suitable, for whatever reason, for VRT, NovaVision provides NeuroEyeCoach on its own for $450.

For Physicians:
·        Vision Diagnostic (VIDIT). The diagnostic component of VRT that enables therapists to perform high-resolution visual field tests in less than 10 minutes to screen for visual field deficits.
·        NeuroEyeCoach Pro Center. Enables stroke rehabilitation and other centers to treat patients while in their care, both as in-patient and out-patient.
·        NovaVision and NeuroEyeCoach Pro Physician. Enables physicians to register patients in their clinic who complete the therapy at home, supported by NovaVision but monitored by the physician through a dedicated portal.

VRT is a prescription product and the only FDA cleared therapy (510k) for the restoration of vision loss from neurological damage. VRT is supported by 15 years of clinical research and over 20 studies including a 302 patient study in which notable improvements were seen in 70% of the patients. NeuroEyeCoach is also clinically supported being based on research that has been the subject of 14 clinical studies on a total of 591 patients and has FDA registration.

Commenting on the Company's announcement, Peter Zachariou, CEO of Vycor, stated: "This has been a long time coming and has entailed an enormous amount of work from both our employees but also our scientific advisors and is a key milestone for NovaVision. We are now finally in a position to deliver our therapies to the large numbers of people who suffer vision loss as a result of neurological brain damage as a cost effective and complete therapy solution. I am convinced that this new therapy suite is the most robust, affordable and complete commercially available visual therapy solution targeted at this type of vision loss.
This also represents the final step in moving NovaVision from being a development company to one focused on commercializing its unique suite of products. I would urge anyone who has had a stroke or brain injury and suffers from a visual disorder to contact us, we have numerous testimonials of patients for whom these therapies have literally changed their lives".

There are approximately 8m stroke survivors in the U.S. with 795,000 strokes a year, and approximately 1.5m suffering some sort of Traumatic Brain Injury (TBI) annually; up to 30% of these suffer a resultant visual impairment, up to 20% permanently. In all, around 2.8 million Americans suffer from this type of vision impairment, which is largely unaddressed by the rehabilitation system. The impact on their daily lives is dramatic, and is the difference between a person being able to be home alone, cross the road unaided, drive, shop or read. The new therapy suite is targeted at this largely underserved group of people.

For an overview of NovaVision see NovaVision Video.


About Vycor Medical, Inc.
With corporate headquarters in Boca Raton, FL, Vycor Medical, Inc. ("Vycor") is a publicly traded company (VYCO) dedicated to providing the medical community with innovative and superior surgical and therapeutic solutions and has a growing portfolio of FDA cleared medical solutions that are changing and improving lives every day. The Company operates two business units: Vycor Medical and NovaVision, both of which adopt a minimally or non-invasive approach. Both technologies have exceptional sales growth potential, address large potential markets, have the requisite regulatory approvals and are commercialized and generating revenue.

Vycor Medical's ViewSite(TM) Surgical Access Systems (VBAS) is a suite of clear cylindrical minimally invasive disposable devices that hold the potential for speedier, safer and more economical brain surgeries and a quicker patient discharge. VBAS is designed to optimize neurosurgical site access, reduce patient risk, accelerate recovery and add tangible value to the professional medical community. The company is ISO 13485:2003 compliant, has U.S. FDA 510(k) clearance for brain and spine surgeries and full regulatory approvals for brain in Australia, Canada, China, Europe (EU - Class III), Korea and Japan and is seeking or has partial regulatory approvals in Brazil, India, Russia, Taiwan and Vietnam. For an overview of Vycor Medical's VBAS see VBAS Video.

NovaVision develops and provides science-driven neurostimulation therapy and other medical technologies that help improve and partially restore sight in patients with neurological vision impairments. The company's proprietary Visual Restoration Therapy(R) (VRT) platform is clinically supported to improve lost vision resulting from stroke, traumatic brain injury (“TBI”), or other acquired brain injuries. VRT is the only FDA 510K cleared medical device in the U.S. aimed at the restoration of vision for neurologically induced vision loss and can be prescribed by any Physician. VRT also has CE Marking for the EU. NovaVision also provides Neuro Eye Therapy (NeET) in the EU, aimed at increasing visual sensitivity deep within the field defect.

The Company has also developed a therapy called NeuroEyeCoach(TM). The NeuroEyeCoach(TM) therapy is highly complementary to VRT(TM). The two therapies address different visual disabilities each of which results from neurologically-induced vision loss - a loss of visual field as well as difficulty with eye movement, affecting the ability to integrate visual information. VRT provides partial restoration of the patient’s lost visual field; NeuroEyeCoach(TM) is designed to increase the efficiency of eye movement and re-train the patients’ ability to integrate visual information between the left and right hand side. For an overview of NovaVision see NovaVision Video.

For the latest information on the company, including media and other coverage, and to learn more, please go online at www.vycormedical.comwww.vycorvbas.com or www.novavision.com.

Safe Harbor Statement
Information in this document constitute forward-looking statements or statements which may be deemed or construed to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words "forecast", "anticipate", "estimate", "project", "intend", "expect", "should", "believe", and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to known and unknown risks, uncertainties and other factors which could cause Vycor Medical's actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in Vycor Medical’s filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to Vycor Medical herein are expressly qualified in their entirety by the above-mentioned cautionary statement. Vycor Medical disclaims any obligation to update forward-looking statements contained in this estimate, except as may be required by law.

Vycor Medical, Inc. Contacts:
6401 Congress Avenue
Suite 140
Boca Raton, FL. 33487
(561) 558-2020
info@vycormedical.com

SOURCE: Vycor Medical, Inc.

For more information on VYCO on Investorideas, please visit: http://www.investorideas.com/CO/VYCO/


Disclaimer/Disclosure: The Investorideas.com newswire is a third party publisher of news as well as creates original content as a news source. Original content created by investor ideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and global syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions and advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. Vycor Medical Inc. (VYCO): June 2, 2015 – The company has retained Investor Ideas for PR, media and news distribution: Five thousand per month, one month with option to renew.
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.